Evaluating dyspnoea in acute heart failure: Progress at last!

European Heart Journal

Volumn 31, Issue 7, 2010, Pages 771-772

  Hogg, Karen J ^a   McMurray, John J V ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; BODY POSITION; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DISEASE EXACERBATION; DYSPNEA; EDITORIAL; HEART FAILURE; HUMAN; PRIORITY JOURNAL; RATING SCALE; SITTING; SUPINE POSITION; SYMPTOM; VISUAL ANALOG SCALE; COMPLICATION;

ACUTE DISEASE; DYSPNEA; HEART FAILURE; HUMANS;

EID: 77950498814     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq015     Document Type: Editorial

References (11)

1. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decom-pensated heart failure. Am Heart J 2003;145(2 Suppl):S26-S33.
2. Socrates T, Mebazaa A. How to measure dyspnea in acute heart failure? Ther Umsch 2009;66:639-642.
3. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Courtney DM, Hasa J, Spinar J, Masip J, Peacock WF, Sliwa K, Gayat E, Filippatos G, Cleland JGF, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-841. First published on 11 November 2009. doi: 10.1093/eurheartj/ehp458.
4. Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, Dargie H. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999;116:1208-1217.
5. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Effects of tezosen-tan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
6. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazzaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M; Acute Heart Failure Syndromes International Working Group. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008;29:816-824.
7. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N; Acute Heart Failure Syndromes International Working Group. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009;157: 957-970.
8. Leidy NK, Wyrwich KW. Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2005;2: 157-165.
9. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2: 105-110.
10. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415.
11. Karras DJ, Sammon ME, Terregino CA, Lopez BL, Griswold SK, Arnold GK. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med 2000;7:327-334.